The unique and highly-regarded expertise of Nexomics' founders, as well as the company's strategy of providing drug discovery services to biotech and pharma companies while developing its own IP and drug candidates, bode well for a successful commercial effort.
Highland Park, NJ (PRWEB) January 21, 2009
Nexomics Biosciences Inc., a recently-formed, New Jersey-based biotechnology company, applies cutting edge platform technologies based on large scale protein production, Nuclear Magnetic Resonance (NMR), and X-ray crystallography for use in drug discovery efforts. The company provides customers with services in bioinformatics, protein production and structural biology for lead discovery, optimization and development programs. In addition, Nexomics Biosciences will also pursue in-house drug discovery projects on proprietary targets to identify novel small molecule therapeutics.
Nexomics Biosciences has signed a comprehensive license agreement with Rutgers, the State University of New Jersey, that provides Nexomics rights to a portfolio of intellectual property, including a suite of bioinformatics software and an early stage antibiotic screening methodology. In addition, the agreement gives Nexomics rights to use and further develop a novel ribosomal RNA methyltransferase assay for identifying specific binding and inhibition of R1mA proteins from bacterial species. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.
An additional agreement has been announced with the Center for Advanced Biotechnology and Medicine (CABM), a research and teaching center that provides Nexomics access to laboratory space and equipment. Under the service agreement, Nexomics Biosciences will have access to a number of scientific facilities supporting molecular biology, fermentation, protein purification, and Nuclear Magnetic Resonance (NMR).
"Together with Prof. Gaetano Monteleone and co-founder Dr. Michael Baran, Rutgers is very excited to create Nexomics as a tool for commercializing promising technologies out of Prof. Monteleone's lab" said Dr. Michael Pazzani, Rutgers' V.P. of Research and Graduate and Professional Education. Dr. Pazzani further added "The unique and highly-regarded expertise of Nexomics' founders, as well as the company's strategy of providing drug discovery services to biotech and pharma companies while developing its own IP and drug candidates, bode well for a successful commercial effort."
About Nexomics Biosciences, Inc.
Nexomics Biosciences focuses on the discovery, development and commercialization of novel drugs for cancer, antiviral, and antibiotic treatments. Additionally, Nexomics also functions as a contract research organization (CRO), offering a broad array of gene-to-structure services to the biopharmaceutical community. By utilizing a fully integrated drug discovery pipeline, Nexomics offers a variety of services from bioinformatics, target profiling, gene cloning, recombinant protein expression, laboratory-scale fermentation, crystallization, NMR structural studies, X-ray crystallographic structural studies, and functional annotation. For more information about Nexomics Biosciences, visit http://www.nexomics.com
About Rutgers the State University of New Jersey's Office of Technology Commercialization
The mission of the Rutgers Office of Technology Commercialization is to work closely and supportively with Rutgers faculty and industry to secure corporate funding for Rutgers University faculty research for the public good as well as to identify, protect and license marketable Rutgers University inventions and intellectual property; and to make available additional discretionary income to Rutgers departments and centers, for furthering University research goals. For more information about the Rutgers Office of Technology Commercialization, visit http://www.otc.rutgers.edu
About The Center for Advanced Biotechnology & Medicine
Founded in 1985 and jointly administered by the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and by Rutgers, The State University of New Jersey, the mission of the Center for Advanced Biotechnology and Medicine (CABM) is to advance knowledge in the life sciences for the improvement of human health. CABM is also designated an advanced technology center by the NJ Commission on Science & Technology and is committed to economic development and public sevice through corporate alliances in research and education and by technology transfer and licensing. Completed in 1990, the 100,000 square foot CABM building is centrally located on the Busch/Piscataway campus. For more information about the CABM, visit http://www.cabm.rutgers.edu